Vigilant Capital Management buys $7,889,398 stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Vigilant Capital Management scooped up 590 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 14, 2016. The investment management firm now holds a total of 193,415 shares of Abbott Laboratories which is valued at $7,889,398.Abbott Laboratories makes up approximately 1.42% of Vigilant Capital Management’s portfolio.

Other Hedge Funds, Including , Country Club Trust Company N.a. reduced its stake in ABT by selling 850 shares or 11.73% in the most recent quarter. The Hedge Fund company now holds 6,394 shares of ABT which is valued at $260,811. Abbott Laboratories makes up approx 0.04% of Country Club Trust Company N.a.’s portfolio.Gillespie Robinson Grimm Inc reduced its stake in ABT by selling 139 shares or 1.59% in the most recent quarter. The Hedge Fund company now holds 8,624 shares of ABT which is valued at $375,144. Abbott Laboratories makes up approx 0.06% of Gillespie Robinson Grimm Inc’s portfolio.Exxonmobil Investment Management Inc Tx reduced its stake in ABT by selling 4,948 shares or 1.3% in the most recent quarter. The Hedge Fund company now holds 375,342 shares of ABT which is valued at $16,128,446. Abbott Laboratories makes up approx 0.34% of Exxonmobil Investment Management Inc Tx’s portfolio.Hefty Wealth Partners boosted its stake in ABT in the latest quarter, The investment management firm added 616 additional shares and now holds a total of 704 shares of Abbott Laboratories which is valued at $30,089. Abbott Laboratories makes up approx 0.02% of Hefty Wealth Partners’s portfolio.

Abbott Laboratories closed down -0.19 points or -0.46% at $40.79 with 88,18,965 shares getting traded on Friday. Post opening the session at $41.17, the shares hit an intraday low of $40.77 and an intraday high of $41.53 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.